In a year impeded by the monumental challenges of a worldwide pandemic yet powered by near-record drug development and approvals, the Drugs to Watch 2021 report has narrowed a wide and tough field to four treatments that could achieve blockbuster status in the next five years. The drugs included in the report, an annual view of powerhouse drug development that Clarivate plc began issuing in 2013, are cited as possibly being well on their way to annual sales of more than $1 billion each.